Textile artist Jeanne Hewell-Chambers shares how trust, advocacy, and quirky support turned her fears about a wet AMD clinical trial into stable vision and reclaimed independence. Jeanne ...
Needham initiated coverage on Ocular Therapeutix Inc (NASDAQ:OCUL), noting the company’s lead asset, Axpaxli, an investigational axitinib-based intravitreal implant for wet age-related macular ...
Nevertheless, the study was limited in its noninterventional and retrospective nature, precluding the ability to establish a causal relationship between brolucizumab treatment and IOI and/or RO. In ...
Hosted on MSN
Which Eye Specialist Treats Wet AMD?
Optometrists (healthcare providers who offer standard eye care) can diagnose wet age-related macular degeneration (AMD) but can't treat it. Therapies for wet AMD are primarily led by ophthalmologists ...
Clearside Biomedical, Inc. announced on March 20, 2025, that it presented findings on its lead clinical program, CLS-AX, a suprachoroidal injectable suspension of axitinib, at the 2025 Wet AMD & ...
Outlook Therapeutics, Inc. has announced a key development in the treatment of wet age-related macular degeneration (wet AMD) with the National Institute for Health and Care Excellence (NICE) ...
Ocular plans to leverage the 505(b)(2) regulatory pathway for new drug approvals which has the potential to shorten the review timeline for AXPAXLI If approved, AXPAXLI could be the first TKI to be ...
Welcome to the AMD Clinical Case Review, a series of case presentations in the field of age-related macular degeneration. In this video, Jay Chhablani, MD, director of clinical research at the UPMC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results